Advertisement
Advertisement
IMMP
Immutep Limited - ADR
3.34
USDSponsored
+0.65
+24.16%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.39
+0.05
+1.59%
Immutep Limited - ADR (IMMP) Earnings
IMMP Earnings Reports
Positive Surprise Ratio
IMMP beat 6 of 11 last estimates.
55%
Next Report
Date of Next Report
Feb 23, 2027
Estimate for Q2 27 (Revenue/ EPS)
$2.66M
/$0.00
Implied change from Q4 26 (Revenue/ EPS)
-83.80%
/-100.00%
Implied change from Q2 26 (Revenue/ EPS)
-65.57%
/-100.00%
Immutep Limited - ADR earnings per share and revenue
On Sep 01, 2026, IMMP reported earnings of -0.02 USD per share (EPS) for Q4 26, missing the estimate of 0.00 USD, resulting in a -2500.00% surprise. Revenue reached 16.43 million, compared to an expected 12.06 million, with a 36.25% difference. The market reacted with a -0.26% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 2 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 2.66 million USD, implying an decrease of -100.00% EPS, and decrease of -83.80% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Immutep Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Immutep Limited - ADR reported EPS of -$0.02, missing estimates by -2500%, and revenue of $16.43M, 36.25% above expectations.
How did the market react to Immutep Limited - ADR's Q4 2026 earnings?
The stock price moved down -0.26%, changed from $0.38 before the earnings release to $0.38 the day after.
When is Immutep Limited - ADR expected to report next?
The next earning report is scheduled for Feb 23, 2027.
What are the forecasts for Immutep Limited - ADR's next earnings report?
Based on 2
analysts, Immutep Limited - ADR is expected to report EPS of -- and revenue of $2.66M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.